Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Meta Expands AI Training With Employee Activity Tracking Tools 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
SAN DIEGO, Feb. 25, 2016 -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and live audio webcast on Thursday, March 3, 2016 at 5:00 p.m. ET to report its fourth quarter and full year 2015 financial results and provide a corporate update.
In order to participate in the conference call, please dial 1-877-303-6235 (domestic) or 1-631-291-4837 (international) and refer to conference ID 58417776. The live webcast can be accessed under "Events & Presentations" in the Investors and Media section of the Company's website at www.fatetherapeutics.com. The archived webcast will be available on the Company's website beginning approximately two hours after the event.
About Fate Therapeutics, Inc.
Fate Therapeutics is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell-based product pipeline is comprised of immuno-oncology therapies, including off-the-shelf NK- and T-cell-based candidates derived from engineered induced pluripotent cells, and immuno-regulatory therapies, including hematopoietic cell-based candidates for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity. Its adoptive cell therapy candidates are based on the Company’s novel ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
Contact: Jesse Baumgartner Stern Investor Relations, Inc. 212.362.1200 [email protected]
